Trial · NCT00792948

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

NCT00792948, Phase 2, Active not recruiting, National Cancer Institute (NCI); results first posted 2017-04-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia. Trials, record NCT00792948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00792948

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
NCT number: NCT00792948
Status: Active not recruiting
Phases: Phase 2
Enrollment: 97 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Methylprednisolone, Peripheral Blood Stem Cell Transplantation, Prednisone, Sirolimus, Tacrolimus, Total-Body Irradiation, Vincristine Sulfate
First posted: 2008-11-18
Last updated: 2026-10-22
Results first posted: 2017-04-26

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation	12 months	Will be estimated using the method of Kaplan-Meier.
Secondary	Continuous Complete Remission (CCR) Rate	18 months	Will be testing using an exact binomial test
Other	Overall Survival (OS)	From the date of initial registration on the study until death from any cause, assessed up to 5 years	OS will be estimated using the method of Kaplan-Meier.
Other	MRD as Assessed Using Real-time Quantitative Polymerase Chain Reaction and Flow Cytometry	Up to 5 years	Correlation between the two measures of MRD measured on the same remission specimens will be examined using scatterplots and correlation analysis. The prognostic effect for relapse of each measure will be illustrated using cumulative incidence plots, and estimated using Cox regression models. This outcome will be reported as funding allows.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation	12 months	Patients who received allogeneic stem cell transplant	Probability of 12-month RFS	NUMBER
SECONDARY	Continuous Complete Remission (CCR) Rate	18 months	Patients who had not received prior ALL therapy	percentage of participants	NUMBER
OTHER_PRE_SPECIFIED	Overall Survival (OS)	From the date of initial registration on the study until death from any cause, assessed up to 5 years	Analysis includes eligible patients who received treatment.	Probability of surviving 12 months	NUMBER
OTHER_PRE_SPECIFIED	MRD as Assessed Using Real-time Quantitative Polymerase Chain Reaction and Flow Cytometry	Up to 5 years

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation	Treatment	0.83	95% Confidence Interval 0.67 to 0.91	Probability of 12-month RFS
Continuous Complete Remission (CCR) Rate	Treatment	57	95% Confidence Interval 43 to 69	percentage of participants
Overall Survival (OS)	Treatment	0.88	95% Confidence Interval 0.80 to 0.93	Probability of surviving 12 months

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment	97
Overall Study	COMPLETED	Treatment	69
Overall Study	NOT COMPLETED	Treatment	28

Source ClinicalTrials.gov

Adverse events968

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Blood/Bone Marrow-Other	Blood and lymphatic system disorders	Induction/Consolidation	5	93
other	Blood/Bone Marrow-Other	Blood and lymphatic system disorders	Vincristine/Prednisone/Dasatinib	1	22
other	Blood/Bone Marrow-Other	Blood and lymphatic system disorders	Allogeneic Stem Cell Transplant	0	4
other	Blood/Bone Marrow-Other	Blood and lymphatic system disorders	Dasatinib	1	39
other	Febrile neutropenia	Blood and lymphatic system disorders	Induction/Consolidation	28	93
other	Febrile neutropenia	Blood and lymphatic system disorders	Vincristine/Prednisone/Dasatinib	1	22
other	Febrile neutropenia	Blood and lymphatic system disorders	Allogeneic Stem Cell Transplant	0	4
other	Febrile neutropenia	Blood and lymphatic system disorders	Dasatinib	1	39
other	Hemoglobin	Blood and lymphatic system disorders	Induction/Consolidation	69	93
other	Hemoglobin	Blood and lymphatic system disorders	Vincristine/Prednisone/Dasatinib	14	22

1 to 10 of 968Source ClinicalTrials.gov

See all 968 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Induction/Consolidation
Total, all-cause mortality	Vincristine/Prednisone/Dasatinib
Total, all-cause mortality	Allogeneic Stem Cell Transplant
Total, all-cause mortality	Dasatinib
Total, other adverse events	Induction/Consolidation	89	93
Total, other adverse events	Vincristine/Prednisone/Dasatinib	22	22
Total, other adverse events	Allogeneic Stem Cell Transplant	0	4
Total, other adverse events	Dasatinib	36	39
Total, serious adverse events	Induction/Consolidation	43	93
Total, serious adverse events	Vincristine/Prednisone/Dasatinib	5	22

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
29618479	DERIVED

Source PubMed

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
U10CA180888	SWOG Network Group Operations Center of the NCTN	LARA, PRIMO N.; HERSHMAN, DAWN	UNIVERSITY OF CALIFORNIA AT DAVIS	NATIONAL CANCER INSTITUTE	2014 to 2026	NIH RePORTER
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00792948

GET https://conductscience.org/api/trials/v1/NCT00792948/events?page=2

API reference For AI assistants